留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

CD24和Siglec-10在上皮性卵巢癌组织中的表达及意义

陈姝 张競 李燕华

陈姝, 张競, 李燕华. CD24和Siglec-10在上皮性卵巢癌组织中的表达及意义[J]. 中华全科医学, 2021, 19(3): 428-431. doi: 10.16766/j.cnki.issn.1674-4152.001828
引用本文: 陈姝, 张競, 李燕华. CD24和Siglec-10在上皮性卵巢癌组织中的表达及意义[J]. 中华全科医学, 2021, 19(3): 428-431. doi: 10.16766/j.cnki.issn.1674-4152.001828
CHEN Shu, ZHENG Jing, LI Yan-hua. The expression and significance of CD24 and Siglec-10 in epithelial ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(3): 428-431. doi: 10.16766/j.cnki.issn.1674-4152.001828
Citation: CHEN Shu, ZHENG Jing, LI Yan-hua. The expression and significance of CD24 and Siglec-10 in epithelial ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(3): 428-431. doi: 10.16766/j.cnki.issn.1674-4152.001828

CD24和Siglec-10在上皮性卵巢癌组织中的表达及意义

doi: 10.16766/j.cnki.issn.1674-4152.001828
基金项目: 

安徽省教育厅高校自然科学研究重点项目 KJ2019A0384

详细信息
    通讯作者:

    李燕华, E-mail: bblyh1964@126.com

  • 中图分类号: R737.31  R730

The expression and significance of CD24 and Siglec-10 in epithelial ovarian cancer

  • 摘要:   目的  分析CD24、Siglec-10在不同卵巢组织中的表达, 探讨两者在上皮性卵巢癌组织中的表达及意义。  方法  通过免疫组织化学(SP)法检测CD24、Siglec-10的表达情况, 分析两者在不同卵巢组织中的表达情况及特点, 探讨CD24、Siglec-10与上皮性卵巢癌不同病理参数之间的关系以及两参数之间的关系, 并结合随访结果探索其与上皮性卵巢癌的发生发展、侵袭转移及复发的关系。  结果  CD24、Siglec-10在正常卵巢组织中不表达, 其表达水平随卵巢肿瘤的良性、交界性、恶性变化而增加, 各组间差异具有统计学意义(均P<0.05);CD24、Siglec-10的表达水平与FIGO分期、淋巴结转移、大网膜转移、盆腹腔种植灶、复发密切相关(均P<0.05);CD24和Siglec-10在上皮性卵巢癌中的高表达水平具有明显相关性(r=0.500, P<0.001)。  结论  CD24和Siglec-10具有协同作用, 能够共同促进卵巢肿瘤的发生发展、侵袭、转移, 并且与复发密切相关; CD24-Siglec-10有望成为新的免疫检测点, 为上皮性卵巢癌在免疫治疗方面提供更多的可能。

     

  • 表  1  CD24、Siglec-10在不同卵巢组织中的表达比较(例)

    组别 例数 组织中CD24的表达 组织中Siglec-10的表达
    - +~+++ 阳性率(%) - +~+++ 阳性率(%)
    卵巢良性肿瘤 26 20 6 23.1 20 6 23.1
    卵巢交界性肿瘤 24 11 13 54.2 8 16 66.7
    卵巢上皮性癌 71 8 63 88.7 7 64 90.1
    χ2 40.093 41.916
    P <0.001 <0.001
    下载: 导出CSV

    表  2  CD24、Siglec-10与上皮性卵巢癌不同临床病理参数之间的关系(例)

    临床病理参数 例数 组织中CD24的表达 组织中Siglec-10的表达
    高表达 低表达 χ2 P 高表达 低表达 χ2 P
    组织学类型 0.999a 0.341a
      浆液性 61 43 18 45 16
      黏液性 6 4 2 3 3
    组织学分级 0.113a 0.124a
      G1级 9 4 5 4 5
      G2、G3级 62 46 16 45 17
    FIGO分期 < 0.001a 15.190 < 0.001
      Ⅰ、Ⅱ期 25 8 17 10 15
      Ⅲ、Ⅳ期 46 42 4 39 7
    淋巴结转移 0.042a 0.030a
      有 8 7 1 7 1
      无 17 7 10 6 11
    大网膜转移 < 0.001a 6.878 0.009
      有 39 36 3 32 7
      无 32 14 18 17 15
    腹水 0.361a 1.085 0.298
      有 54 36 18 39 15
      无 17 14 3 10 7
    盆腹腔种植灶 14.040 <0.001 17.001 <0.001
      有 52 43 9 43 9
      无 19 7 12 6 13
    注:a为采用Fisher精确检验。
    下载: 导出CSV

    表  3  CD24与Siglec-10表达的相关性(例)

    CD24 Siglec-10 r P
    高表达 低表达
    高表达 42 8 0.500 <0.001
    低表达 7 14
    下载: 导出CSV

    表  4  CD24、Siglec-10的表达与复发的关系(例)

    复发情况 例数 CD24表达 Siglec-10表达
    高表达 低表达 高表达率(%) P 高表达 低表达 高表达率(%) P
    43 34 9 79.1 0.048a 32 11 74.4 0.045a
    9 4 5 44.4 3 6 33.3
    注:a为采用Fisher精确检验。
    下载: 导出CSV
  • [1] NAKAMURA K, TERAI Y, TANABE A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways[J]. Oncol Rep, 2017, 37(6): 3189-3200. doi: 10.3892/or.2017.5583
    [2] EISENHAUER E A. Real-world evidence in the treatment of ovarian cancer[J]. Ann Oncol, 2017, 28(suppl 8): 1161-1165. http://www.ncbi.nlm.nih.gov/pubmed/28574933
    [3] PIGNATA S, CECERE C S, BOIS A D, et al. Treatment of recurrent ovarian cancer[J]. Ann Oncol, 2017, 28(suppl 8): 51-56.
    [4] MORGAN R J, ARMSTRONG D K, ALVAREZ R D, et al. Ovarian cancer, Version 1.2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2016, 14(9): 1134-1163. doi: 10.6004/jnccn.2016.0122
    [5] TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296. doi: 10.3322/caac.21456
    [6] HENDERSON J T, WEBBER E M, SAWAYA G F. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force[J]. JAMA, 2018, 319(6): 595-606. doi: 10.1001/jama.2017.21421
    [7] DUEX J E, OWENS C, CHAUCA-DIAZ A, et al. Nuclear CD24 drives tumor growth and is predictive of poor patient prognosis[J]. Cancer Res, 2017, 77(18): 4858-4867. doi: 10.1158/0008-5472.CAN-17-0367
    [8] BARKAL A A, BREWER R E, MARKOVIC M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy[J]. Nature, 2019, 572(7769): 392-396. doi: 10.1038/s41586-019-1456-0
    [9] PEI Z, ZHU G, HUO X, et al. CD24 promotes the proliferation and inhibits the apoptosis of cervical cancer cells in vitro[J]. Oncol Rep, 2016, 35(3): 1593-1601. doi: 10.3892/or.2015.4521
    [10] ROSTOKER R, ABELSON S, GENKIN I, et al. CD24(+) cells fuel rapid tumor growth and display high metastatic capacity[J]. Breast Cancer Res, 2015, 17(1): 78. doi: 10.1186/s13058-015-0589-9
    [11] EYVAZI S, KAZEMI B, DASTMALCHI S, et al. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy[J]. Curr Cancer Drug Targets, 2018, 18(4): 328-336. doi: 10.2174/1570163814666170818125036
    [12] DENG X, APPLE S, ZHAO H, et al. CD24 Expression and differential resistance to chemotherapy in triple -negative breast cancer[J]. Oncotarget, 2017, 8(24): 38294-38308. doi: 10.18632/oncotarget.16203
    [13] KWON M J, HAN J, SEO J H, et al. CD24 Overexpression is associated with poor prognosis in luminal a and triple-negative breast cancer[J]. PLoS One, 2015, 10(10): e0139112. doi: 10.1371/journal.pone.0139112
    [14] YANG X R, XU Y, YU B, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery[J]. Clin Cancer Res, 2009, 15(17): 5518-5527. doi: 10.1158/1078-0432.CCR-09-0151
    [15] KRISTIANSEN G, SCHLVNS K, YONGWEI Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients[J]. Br J Cancer, 2003, 88(2): 231-236. doi: 10.1038/sj.bjc.6600702
    [16] LIU C, ZHENG S, SHEN H, et al. Clinical significance of CD24 as a predictor of bladder cancer recurrence[J]. Oncol Lett, 2013, 6(1): 96-100. doi: 10.3892/ol.2013.1357
    [17] OVERDEVEST J B, KNUBEL K H, DUEX J E, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated[J]. Proc Natl Acad Sci U S A, 2012, 109(51): 3588-3596. doi: 10.1073/pnas.1113960109
    [18] LI Y, ZHOU J, ZHUO Q, et al. Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression[J]. Cancer Manag Res, 2019, 11(4): 7123-7134. http://www.ncbi.nlm.nih.gov/pubmed/31534365
    [19] ABRAM C L, LOWELL C A. Shp1 function in myeloid cells[J]. J Leukoc Biol, 2017, 102(3): 657-675. doi: 10.1189/jlb.2MR0317-105R
    [20] KLEMBA A, PURZYCKA-OLEWIECKA J K, WCISO G, et al. Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance[J]. Contemp Oncol(Pozn), 2018, 22(1A): 48-55. http://www.termedia.pl/Journal/-77/pdf-32001-10?filename=Surface%20markers%20of%20cancer.pdf
    [21] NAKAMURA K, TERAI Y, TANABE A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways[J]. Oncol Rep, 2017, 37(6): 3189-3200. doi: 10.3892/or.2017.5583
    [22] 刘恒炜, 吕立群. 基于Oncomine数据库荟萃分析CD24在卵巢癌中的表达和临床意义[J]. 国际妇产科学杂志, 2019, 46(5): 580-584. doi: 10.3969/j.issn.1674-1870.2019.05.025
  • 加载中
表(4)
计量
  • 文章访问数:  221
  • HTML全文浏览量:  155
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-10-15
  • 网络出版日期:  2022-02-19

目录

    /

    返回文章
    返回